Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

• Published in: CPT: pharmacometrics and systems pharmacology Vol. 10; no. 10; pp. 1245 - 1254
• Main Authors: Galluppi, Gerald R., Polhamus, Daniel G., Fisher, Jeannine M., Hopkins, Seth C., Koblan, Kenneth S.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.10.2021; John Wiley and Sons Inc; Wiley
• Subjects: Adolescent; Adult; Asian people; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dopamine; Drug dosages; Female; GLP-1 receptor agonists; Healthy Volunteers; Humans; Male; Mental disorders; Middle Aged; Patients; Pharmacokinetics; Plasma; Population; Psychotropic drugs; Pyrans - pharmacokinetics; Pyrans - therapeutic use; Receptor, Serotonin, 5-HT1A; Receptors, G-Protein-Coupled - agonists; Schizophrenia; Schizophrenia - drug therapy; Serotonin 5-HT1 Receptor Agonists - pharmacokinetics; Serotonin 5-HT1 Receptor Agonists - therapeutic use; Young Adult; United States > US

Ulotaront (SEP‐363856) is a trace amine–associated receptor 1 agonist with 5‐HT1A agonist activity in phase III development for the treatment of schizophrenia. The efficacy of ulotaront is not mediated by blockade of D2 or 5‐HT2A receptors. The aim of this study was to evaluate the population pharma...